Background: Rheumatoid arthritis (RA) is the most common inflammatory arthritis that can cause damage to the joints. Aim: To study the prevalence of arthritis flare among rheumatoid Arthritis patients after (2-doses) SARS–CoV-2 mRNA vaccination in Aswan university hospital. Patients and methods: This prospective study was conducted on 150 rheumatoid arthritis patients diagnosed according to ACR/EULAR 2010 rheumatoid arthritis classification criteria and ACR 1987 classification criteria of rheumatoid arthritis was recorded in the rheumatology out-patient clinic in Aswan University Hospital form the period from September 2021 to August 2022. Results: There was statistically significant increase in arthralgia, ESR and DAS 28 score after vaccination (p-Value <0.05), while there was no statistically significant difference in arthritis score before and after vaccination (p-Value >0.05). Conclusion: Pre-vaccination disease activity evaluation revealed arthralgia mean of 0.53 ± 0.78, ranging from 0 to 3, and arthritis mean of 0.08 ± 0.3, ranging from 0 to 2. For DAS 28, the mean was 2.42 ± 0.22, ranging from 1.06 to 2.6. Following the COVID-19 vaccine, 84.7% of RA patients used HCQ, 66.7% used MTX, and 22.7% used steroids. Only 6 (4% of biologically treated patients)